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BACKGROUND: This study was designed to investigate the genetic evidence for repurposing of GLP1R (glucagon- like peptide- 1 
receptor) agonists to prevent heart failure (HF) and whether the potential benefit exceeds the benefit conferred by more gen-
eral glycemic control.
METHODS AND RESULTS: We applied 2- sample Mendelian randomization of genetically proxied GLP1R agonism on HF as 
the main outcome and left ventricular ejection fraction as the secondary outcome. The associations were compared 
with those of general glycemic control on the same outcomes. Genetic associations were obtained from genome- wide 
association study summary statistics of type 2 diabetes mellitus (228 499 cases and 1 178 783 controls), glycated hemo-
globin (n=344 182), HF (47,309 cases and 930 014 controls), and left ventricular ejection fraction (n=16 923). Genetic 
proxies for GLP1R agonism associated with reduced risk of HF (odds ratio per 1 mmol/mol decrease in glycated hemo-
globin 0.75; 95% CI, 0.64– 0.87; P=1.69×10−4), and higher left ventricular ejection fraction (SD change in left ventricular 
ejection fraction per 1 mmol/mol decrease in glycated hemoglobin 0.22%; 95% CI, 0.03– 0.42; P=0.03). The magnitude 
of these benefits exceeded those expected from improved glycemic control more generally. The results were similar in 
sensitivity analyses, and we did not find evidence to suggest that these associations were mediated by reduced coronary 
artery disease risk.
CONCLUSIONS: This genetic evidence supports the repurposing of GLP1R agonists for preventing HF.
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Patients with type 2 diabetes mellitus are at in-creased risk of developing heart failure and evi-dence from randomized controlled trials supports 
that GLP1R (glucagon- like peptide- 1 receptor) agonists 
reduce this risk.1,2 The aim of this study was to leverage 
human genetic data within the Mendelian randomiza-
tion paradigm to investigate whether effects of GLP1R 
agonists on heart failure risk and left ventricular ejection 
fraction (LVEF) exceed those of improved glycemic con-
trol more generally.
METHODS
All data used in this work are publicly available and an-
onymized. All contributing studies received appropri-
ate ethical approval and patient consent.
Methodologic Overview
The Mendelian randomization (MR) approach uses 
genetic variants as proxies to investigate the causal 
effect of an exposure on an outcome.3,4 This method 
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leverages the random allocation of genetic variants 
at conception to reduce any bias due to confounding 
and reverse causation that can limit causal inference 
in observational research. MR can be extended to in-
vestigate drug effects by leveraging genetic variation in 
genes (eg, GLP1R) encoding proteins corresponding 
to drug targets.5
Genetic Proxies for GLP1R Agonism and 
Glycemic Control
We identified genetic proxies for the effect of GLP1R 
agonism as genome- wide significant (P<5×10−8) 
and uncorrelated (r2<0.1) variants in the GLP1R gene 
(genomic position on build GRCh37/hg19: chromo-
some 6:39 016 574– 39 055 519) that associated with 
type 2 diabetes mellitus liability in the largest pub-
lished genome- wide association study meta- analysis 
(228 499 cases and 1 178 783 controls; 79% European 
ancestry),6 with directionally concordant and nominally 
significant (P<0.05) associations with glycated hemo-
globin in the UK Biobank (n=344 182).7 Unless other-
wise stated, all downstream analyses were weighted 
by the variant association with glycated hemoglobin 
(mmol/mol). These variants were annotated for their 
sequence effects (eg, intron or missense), and we 
queried the Genotype- Tissue Expression v8 data set 
of 54 tissue types to determine whether the variants 
were associated with gene expression.8 Variants were 
annotated as having directionally concordant associa-
tions with gene expression if they were associated with 
lower glycated hemoglobin and greater expression of 
GLP1R (or vice versa).
Genetic proxies for glycemic control more gener-
ally were identified through the same associations but 
considering genetic variants throughout the genome 
that were not located within 1megabase of GLP1R. 
Given the larger number of variants identified from 
throughout the genome, we used a stricter clumping 
threshold of r2<0.001 to minimize bias due to linkage 
disequilibrium.
Heart Failure and Left Ventricular Ejection 
Fraction Genetic Association Estimates
Heart failure was the primary outcome for our analysis. 
We obtained genetic association estimates from the 
Heart Failure Molecular Epidemiology for Therapeutic 
Targets Consortium consisting of 47  309 cases and 
930  014 controls of European ancestry.9 Cases in-
cluded patients with a clinical diagnosis of heart failure, 
irrespective of the ejection fraction. We further investi-
gated LVEF as a secondary outcome using genetic as-
sociation estimates from a study of cardiac magnetic 
resonance imaging derived LVEF in the UK Biobank 
(n=16  923, all of European ancestry).10 LVEF was in-
verse normal- transformed, and the genetic association 
estimates are therefore presented in approximate SD 
units.
Statistical Analysis
For each of the variants used in MR analysis, we har-
monized genetic associations with the exposure and 
outcome by aligning effect alleles, with no exclusion 
made for palindromic variants. We derived MR esti-
mates considering genetically proxied GLP1R ago-
nism and glycemic control more generally using the 
random- effects inverse- variance weighted method 
with intercept fixed at the origin,3 orientating estimates 
to reduction in glycated hemoglobin (ie, the direction of 
drug effect). All MR analyses were performed using the 
TwoSampleMR package in R.3 To assess for a GLP1R 
agonism drug class effect that exceeds the anticipated 
effect of glycemic control more generally, we tested for 
a significant difference between the respective MR es-
timates. The point estimate for this difference was ob-
tained by taking the difference between the MR beta 
coefficients for the GLP1R and glycemic control esti-
mates, and the SE for the difference was derived using 
the propagation of error method:
where GLP1R and GLYCEMIA are the MR estimates for 
the associations of genetically proxied GLP1R agonism 
and glycemic control with the outcomes.
Analyses investigating LVEF as a secondary out-
come were considered exploratory, and so the P val-
ues were not corrected for multiple comparisons. All 
hypothesis tests were 2 sided.
Sensitivity Analyses
In sensitivity analyses considering GLP1R agonism 
we restricted the genetic proxies to coding variation 
in GLP1R, as these variants more plausibly relate to 
GLP1R function. Corresponding MR estimates that 
used a single proxy variant were derived using the 
Wald ratio with first- order SEs. We also performed 
analyses excluding any coding variants to ensure that 
they were not solely driving the MR estimates. To de-
termine whether results were sensitive to our choice to 
weight the variants by their associations with glycated 
hemoglobin, we also performed analyses weighted by 
the log- odds of type 2 diabetes mellitus liability. MR 
estimates may be biased by horizontal pleiotropy if the 
genetic variants proxying GLP1R agonism influence 
heart failure risk or LVEF through a pathway independ-
ent of GLP1R agonism. We first tested for any such 
bias by calculating the Cochran Q test P value to as-
sess for overdispersion in the MR estimates provided 
by each variant in the GLP1R agonism instrument. We 
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method, which provides consistent MR estimates if 
more than half of the weight from the genetic proxies 
comes from valid instrumental variables.11
To determine whether protective effects of GLP1R 
agonism on heart failure may be mediated by reduced 
coronary artery disease risk, we performed MR anal-
yses investigating the effect of GLP1R agonism on 
coronary artery disease risk. We obtained genetic 
association estimates from a meta- analysis of data 
from the CARDIOGRAMplusC4D Consortium and UK 
Biobank consisting of 122  733 cases and 424  528 
controls of European ancestry.12
RESULTS
Identification of Genetic Proxies for 
GLP1R Agonism and Glycemic Control 
More Generally
Three independent variants in GLP1R were identi-
fied as genetic proxies for GLP1R agonism, includ-
ing 1 missense variant (rs10305420) and 2 intronic 
variants (rs2268647 and rs75151020; Tables S1– S2). 
Two of these variants were significantly associated 
with expression of GLP1R across several human tis-
sues, and both variants had directionally concordant 
associations with GLP1R expression in pancreatic 
tissue (Table S3). A directionally discordant associa-
tion with GLP1R expression in left ventricular and left 
atrial appendage myocardial tissue was identified for 
the intronic variant rs2268647 (Table S3). There were 
350 variants available for use as proxies for glycemic 
control more generally in the heart failure data set 
(Table S4) and 334 variants available in the LVEF data 
set (Table S5).
Mendelian Randomization Analyses
Genetically proxied GLP1R agonism associated 
with a reduced risk of heart failure (odds ratio [OR] 
per 1  mmol/mol decrease in glycated hemoglobin, 
0.75; 95% CI, 0.64– 0.87; P=1.69×10−4). This estimate 
was similar in MR analysis only using the missense 
variant rs10305420 (OR, 0.62; 95% CI, 0.45– 0.85; 
P=2.59×10−3). Analyses excluding this variant provided 
similar evidence of effect, suggesting that this variant 
did not solely drive the estimates (OR, 0.79; 95% CI, 
0.67– 0.92; P=3.33×10−3). Consistent with previous 
reports,9 a genetically proxied improvement in overall 
glycemic control associated with reduced risk of heart 
failure (OR, 0.96; 95% CI, 0.94– 0.97; P=7.75×10−11). 
This estimate was smaller in magnitude than the esti-
mate obtained for genetically proxied GLP1R agonism 
(Pdifference=1.58×10
−3; Figure).
Genetically proxied GLP1R agonism associated 
with a higher LVEF (SD change in LVEF, 0.22; 95% 
CI, 0.03– 0.42; P=0.03). There was no evidence of 
an association between genetically proxied glycemic 
control more generally and LVEF (SD change in LVEF, 
0.00; 95% CI, −0.01 to 0.02; P=0.67). This estimate 
was smaller in magnitude than that obtained for ge-
netically proxied GLP1R agonism (Pdifference=0.03). 
Corresponding scatter plots for all analyses are pro-
vided in Figures S1– S5.
Figure. Forest plot depicting Mendelian randomization estimates for the association of genetically proxied GLP1R 
(glucagon- like peptide receptor) agonism and glycemic control more generally with (A) risk of heart failure (HF; 47  309 
cases/930 014 controls) and (B) left ventricular ejection fraction (LVEF; n=16 923).
Estimates reflect the effect of a reduction in glycated hemoglobin on each of the respective outcomes (so as to orient estimates to 
GLP1R agonist drug effects). Squares correspond to point estimates, and the surrounding lines correspond to 95% CIs. diff indicates 
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Sensitivity Analyses
Analyses weighting the genetic proxies for GLP1R 
agonism (OR per log- odds increase in type 2 dia-
betes mellitus liability, 0.48; 95% CI, 0.34– 0.67; 
P=2.87×10−5) and overall glycemic control (OR, 0.90; 
95% CI, 0.87– 0.93; P=1.81×10−12) by type 2 diabe-
tes mellitus liability showed similar evidence for a re-
duction in heart failure risk. There was no significant 
heterogeneity in the MR estimates generated by the 
different variants when considering either heart failure 
or LVEF as outcomes (Figures S1– S3). Results from 
analyses using the weighted median method showed 
significant protective associations of genetically 
proxied GLP1R agonism (OR, 0.77; 95% CI, 0.62– 
0.96; P=0.02) and improved glycemic control (OR, 
0.98; 95% CI, 0.96– 1.00; P=0.04) with heart failure 
risk, and directionally concordant but nonsignificant 
associations of genetically proxied GLP1R agonism 
with LVEF (SD change in LVEF, 0.18; 95% CI, −0.07 
to 0.42; P=0.16; Table S6). We found no evidence for 
an association of genetically proxied GLP1R agonism 
with coronary artery disease risk (OR per 1 mmol/
mol decrease in glycated hemoglobin, 1.02; 95% CI, 
0.89– 1.16; P=0.80).
DISCUSSION
In this MR study, we used human genetic data to iden-
tify proxies for GLP1R agonism and found evidence for 
their protective effect on risk of heart failure. In sec-
ondary analyses, we found associations of genetically 
proxied GLP1R agonism with increased LVEF. The 
magnitude of these estimates exceeded those gener-
ated using genetic proxies for glycemic control more 
generally, supporting a role for GLP1R signaling in 
preventing heart failure beyond an effect on glycemic 
control alone.13 We did not find evidence of heteroge-
neity in the MR estimates generated by the genetic 
proxies for GLP1R agonism when considering either 
heart failure or LVEF as outcomes, and results were 
similar in sensitivity analyses using the weighted me-
dian method, with the null effect of GLP1R agonism 
on LVEF potentially attributable to low statistical power. 
The null effect of genetically proxied GLP1R agonism 
on coronary artery disease risk suggests that a re-
duced risk of heart failure is not attributable to chronic 
ischemic heart disease.
Our findings are consistent with meta- analyses of 
randomized controlled trials identifying a protective 
effect of GLP1R agonists on hospital admission with 
heart failure1,2 and go further to provide genetic evi-
dence supporting a drug effect on LVEF. Further clin-
ical research is needed to determine contexts where 
GLP1R agonists may be repurposed for reducing 
risk of heart failure, particularly given the established 
effects of sodium glucose cotransporter 2 inhibitors for 
reducing progression of heart failure in patients with 
and without type 2 diabetes mellitus.14
A similar genetic approach was previously used 
to support a protective effect of GLP1R agonism on 
coronary artery disease risk15; however, our analyses 
did not replicate this finding. The previous investigation 
used a low- frequency missense variant, rs10305492, 
which is not in strong linkage disequilibrium with any 
of the variants included in our investigation (all pairwise 
r2<0.16). We did not select this variant for inclusion 
in our analysis as its association with type 2 diabe-
tes mellitus achieved only a nominal level of statisti-
cal significance (P=0.001), and not the more stringent 
genome- wide level of statistical significance achieved 
by the variants in our investigation. In contrast, meta- 
analyses of clinical trials have supported a nominally 
significant (P=0.043 before adjustment for multiple 
comparisons) beneficial effect of GLP1R agonism on 
myocardial infarction.1 Given the small magnitude of 
this reported effect (hazard ratio, 0.91; 95% CI, 0.84– 
1.001) and the span of the CIs from our MR estimates 
(95% CI, 0.89– 1.16), it is plausible that the null MR es-
timate for coronary artery disease is attributable to low 
statistical power.
The key strength of our work is the use of ran-
domly allocated genetic proxies to study the effects 
of GLP1R agonism. The genetic proxies used in 
these analyses were further validated by their asso-
ciations with glycated hemoglobin, which reduces 
risk of bias due to winner’s curse and permits the 
contextualization of the MR estimates on the gly-
cated hemoglobin scale. The genetic associations 
with LVEF were adjusted for body mass index, which 
allowed standardization for body size. A study limita-
tion is the absence of available large- scale genetic 
summary data for heart failure subtypes. Although 
we used a missense variant in GLP1R (rs10305420) 
and gene expression data to strengthen the validity 
of our findings, further experimental work is neces-
sary to determine the mechanism by which these 
variants influence GLP1R expression or function. In 
particular, the directionally concordant association of 
the rs2268647 intronic variant on gene expression 
in the pancreas, but discordant effect on GLP1R ex-
pression in myocardial tissue warrants further explo-
ration. The MR estimates reflect the consequence 
of a lifelong genetic perturbation of GLP1R signaling 
and cannot be extrapolated to predict the magnitude 
of effect from shorter, discrete pharmacological in-
terventions. The limited number of genetic variants 
available to instrument GLP1R agonism precluded 
more extensive sensitivity analyses for horizontal plei-
otropy. In particular, modeling an intercept term (as 
in the MR- Egger regression approach) can in some 
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pleiotropy but was not appropriate in our analysis of 
GLP1R agonism because of the availability of only 
3 genetic proxies. We used summary- level genetic 
associations with heart failure and LVEF and there-
fore could not perform stratified analyses, such as by 
sex or diabetes mellitus status. Finally, these genetic 
data were predominantly gathered from individuals of 
European ancestry and these results may therefore 
not generalize to other ethnic groups.
CONCLUSIONS
In conclusion, we identified genetic proxies for the ef-
fects of GLP1R agonism, and applied these proxies in 
MR analyses to generate evidence supporting a pro-
tective effect on risk of heart failure. Further investiga-
tion of GLP1R agonist repurposing to prevent heart 
failure in the context of clinical trials is warranted.
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Table S1. Genetic proxies for GLP1R agonism, and estimates for their association with glycated hemoglobin, 
type 2 diabetes, heart failure, and left ventricular ejection fraction.  
 
      Glycated hemoglobin 
 





Left ventricular ejection 
fraction 
 
SNP Chr Position EA OA EAF Beta SE P Beta SE P Beta SE P Beta SE P 
rs10305420* 6 39016636 T C 0.39 -0.051 0.016 1.30x10-3 -0.032 0.004 5.11x10-14 -0.024 0.008 2.63x10-3 -0.009 0.011 4.1x10-1 
rs75151020 6 39031592 C A 0.09 0.119 0.026 7.08x10-6 0.041 0.007 1.37x10-9 -0.022 0.013 1.04x10-1 0.040 0.019 3.4x10-2 
rs2268647 6 39043178 T C 0.52 0.066 0.015 1.51x10-5 0.021 0.004 4.95x10-8 0.019 0.007 1.12x10-2 0.008 0.011 4.4x10-1 
 
Chr: chromosome; EA: effect allele; EAF: effect allele frequency; OA: other allele; SE: standard error; SNP: single 
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Table S2. Linkage disequilibrium r2 values for variants used as proxies for GLP1R agonism.  
 
rsID rs10305420 rs75151020 rs2268647 
rs10305420 1.00 0.01 0.00 
rs75151020 0.01 1.00 0.07 
rs2268647 0.00 0.06 1.00 
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Table S3. Genetic proxies for GLP1R agonism, and estimates for their association with gene expression in the 










GLP1R rs10305420 2.10E-09 0.23 Yes Nerve - Tibial 
GLP1R rs10305420 3.80E-06 0.26 Yes 
Adipose - Visceral 
(Omentum) 
GLP1R rs10305420 4.10E-06 0.25 Yes Thyroid 
GLP1R rs10305420 2.30E-05 0.24 Yes Pancreas 
GLP1R rs2268647 1.00E-09 0.31 No Heart - Left Ventricle 
GLP1R rs2268647 2.10E-07 0.23 No Heart - Atrial Appendage 
GLP1R rs2268647 3.40E-07 -0.33 Yes Stomach 
GLP1R rs2268647 2.10E-06 -0.27 Yes Pancreas 
GLP1R rs2268647 1.60E-05 -0.23 Yes Thyroid 
ANKRD18EP rs2268647 2.20E-05 -0.12 Yes 
Skin - Sun Exposed (Lower 
leg) 
 
rs75151020 did not significantly influence gene expression in any of the tissues in the GTEx database. Variants were 
annotated as directionally concordant if they were associated with lower glycated hemoglobin and higher expression of 
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Table S4. Genetic proxies for glycemic control by any mechanism, and estimates for their association with 
glycated hemoglobin (for the outcome of heart failure).  
 





EAF Beta SE 
rs2482506 10 104563743 G C 0.25 -0.053 0.018 
rs79364741 10 114666651 T C 0.01 -0.164 0.073 
rs11196174 10 114734096 G A 0.29 0.252 0.017 
rs149692182 10 114752674 T C 0.02 0.309 0.053 
rs35676242 10 114757314 A C 0.05 0.230 0.036 
rs11257655 10 12307894 T C 0.21 0.219 0.019 
rs946859 10 13565429 A G 0.47 -0.075 0.015 
rs3122231 10 44027356 C T 0.65 0.050 0.016 
rs113899647 10 64850074 T C 0.03 -0.189 0.044 
rs949693 10 70354574 A G 0.61 -0.050 0.016 
rs11592899 10 71333783 A G 0.34 -0.055 0.016 
rs2812535 10 71456857 A G 0.62 0.069 0.016 
rs697239 10 80947438 C T 0.46 -0.105 0.015 
rs11201992 10 88117318 A C 0.46 -0.038 0.015 
rs1111875 10 94462882 T C 0.41 -0.181 0.016 
rs66536955 10 94737667 C T 0.26 0.044 0.017 
rs34041345 10 99174580 G T 0.26 0.060 0.018 
rs529623 11 117693255 C T 0.52 -0.059 0.015 
rs10893830 11 128044159 T C 0.13 -0.058 0.023 
rs10750397 11 128234144 G A 0.72 -0.040 0.017 
rs67232546 11 128398938 T C 0.21 0.067 0.019 
rs117316450 11 14518419 G C 0.02 0.316 0.054 
rs757110 11 17418477 A C 0.64 -0.112 0.016 
rs11042987 11 2201059 A C 0.58 -0.034 0.016 
rs10831668 11 2288412 T C 0.02 0.234 0.060 
rs231362 11 2691471 G A 0.52 0.120 0.015 
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rs60808706 11 2857233 A G 0.05 -0.227 0.035 
rs2289488 11 2892955 C G 0.40 0.040 0.016 
rs62618693 11 32956492 T C 0.05 -0.144 0.037 
rs523472 11 35031668 A G 0.72 -0.056 0.017 
rs3816605 11 47857253 C T 0.45 -0.080 0.015 
rs7483027 11 58128015 C T 0.38 -0.061 0.016 
rs174541 11 61565908 C T 0.36 -0.098 0.016 
rs1143756 11 65299595 G A 0.29 0.100 0.017 
rs3918296 11 69459036 G C 0.03 -0.249 0.049 
rs11602873 11 72460762 T A 0.16 -0.187 0.021 
rs11236524 11 75464344 C T 0.09 0.069 0.027 
rs4945090 11 76205018 A T 0.60 0.036 0.016 
rs12802861 11 8387806 T C 0.28 -0.052 0.017 
rs10830963 11 92708710 G C 0.28 0.297 0.017 
rs3020069 11 93057087 A G 0.68 0.093 0.016 
rs1426371 12 108629780 A G 0.26 -0.074 0.018 
rs79310463 12 118406696 T C 0.13 0.104 0.023 
rs56348580 12 121432117 C G 0.31 -0.037 0.017 
rs7975763 12 123604053 T C 0.20 -0.057 0.019 
rs11614914 12 133070294 T C 0.33 0.078 0.016 
rs12828318 12 133766122 G A 0.18 -0.057 0.020 
rs10841886 12 21864377 C T 0.23 -0.082 0.018 
rs1480029 12 26356032 A G 0.46 0.042 0.015 
rs3751239 12 27963676 G C 0.20 -0.160 0.019 
rs11063018 12 4288001 C T 0.17 0.067 0.020 
rs74862545 12 4365572 T C 0.02 -0.279 0.052 
rs76895963 12 4384844 G T 0.02 -1.037 0.059 
rs2732469 12 48712932 A T 0.43 -0.258 0.015 
rs61937817 12 57212823 G T 0.11 0.060 0.024 
rs11173646 12 61250814 T A 0.82 -0.046 0.020 
rs2257883 12 66216162 A G 0.13 0.150 0.023 
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rs10879261 12 71520761 G T 0.41 0.068 0.016 
rs11108094 12 95928113 A C 0.07 0.099 0.030 
rs6538805 12 97849120 C T 0.39 -0.076 0.016 
rs9587811 13 109946882 A C 0.41 -0.056 0.016 
rs314879 13 23309382 T C 0.79 -0.069 0.019 
rs34584161 13 26776999 G A 0.24 -0.063 0.018 
rs380854 13 33574631 A G 0.58 -0.058 0.016 
rs9316500 13 51094114 G T 0.29 -0.067 0.017 
rs7991679 13 58691107 A T 0.16 -0.081 0.021 
rs1215451 13 80715893 A G 0.29 -0.131 0.017 
rs112324411 14 101258584 T C 0.07 -0.101 0.032 
rs2295388 14 101309759 A G 0.22 -0.073 0.019 
rs4906272 14 103376031 T C 0.16 0.046 0.021 
rs12883788 14 33303540 T C 0.46 0.060 0.015 
rs7147483 14 38804675 C T 0.25 -0.158 0.018 
rs723355 14 47304091 A G 0.50 -0.034 0.015 
rs4902002 14 61229411 A G 0.71 -0.034 0.017 
rs242105 14 69459229 C A 0.28 0.062 0.017 
rs7156625 14 79942647 A G 0.22 0.037 0.019 
rs8010382 14 91963722 G A 0.41 0.046 0.016 
rs8043085 15 38828140 T G 0.23 0.071 0.018 
rs11856877 15 40620560 G A 0.11 0.071 0.024 
rs1473781 15 41818917 A G 0.35 0.067 0.016 
rs149336329 15 52587740 T G 0.05 -0.272 0.037 
rs7163757 15 62391608 T C 0.43 -0.042 0.015 
rs7178762 15 63871292 T C 0.55 -0.057 0.015 
rs9479 15 74328576 G A 0.49 0.052 0.015 
rs8033589 15 75596685 A G 0.76 0.058 0.018 
rs12910361 15 77782335 G A 0.71 0.161 0.017 
rs893617 15 90381278 T C 0.72 -0.136 0.017 
rs2290202 15 91512267 T G 0.13 0.085 0.023 
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rs8056890 16 28897452 A G 0.36 0.105 0.016 
rs8054556 16 29958216 A G 0.47 0.077 0.015 
rs55857387 16 300388 C T 0.20 -0.142 0.019 
rs8061528 16 3656482 T C 0.21 0.092 0.019 
rs2024449 16 53494617 C T 0.44 -0.056 0.015 
rs1421085 16 53800954 C T 0.40 0.154 0.016 
rs56125990 16 69742387 G A 0.15 0.065 0.021 
rs4788815 16 71634811 T A 0.66 0.056 0.016 
rs72802365 16 75246035 C G 0.08 -0.163 0.029 
rs2966117 16 81599271 T G 0.48 0.059 0.015 
rs11117364 16 88132199 G A 0.68 0.066 0.017 
rs9937296 16 88554480 C T 0.86 0.069 0.023 
rs66461358 16 89535257 C T 0.15 0.060 0.021 
rs12934854 16 950028 A G 0.17 0.043 0.020 
rs925095 17 17344653 T C 0.39 -0.075 0.016 
rs2297508 17 17715317 G C 0.65 -0.150 0.016 
rs117642733 17 21284910 T C 0.05 0.107 0.039 
rs9913225 17 27570622 A G 0.58 -0.075 0.016 
rs1109442 17 34862220 C T 0.47 0.071 0.015 
rs3110641 17 36047417 G A 0.78 0.091 0.019 
rs11651755 17 36099840 T C 0.51 -0.124 0.015 
rs3786017 17 3830340 C T 0.11 0.054 0.025 
rs8071043 17 3988451 C T 0.33 0.066 0.016 
rs1905339 17 40582296 C T 0.34 0.097 0.016 
rs35895680 17 47060322 A C 0.33 -0.089 0.016 
rs366577 17 4854480 T C 0.60 -0.051 0.016 
rs57767539 17 62203059 A G 0.07 0.136 0.031 
rs11658220 17 65646092 A G 0.10 0.100 0.025 
rs12603589 17 65825248 C T 0.19 0.103 0.020 
rs7224711 17 76772288 T C 0.53 -0.069 0.015 
rs303760 18 21083738 T C 0.35 0.052 0.016 
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rs7227272 18 36746623 A G 0.10 -0.062 0.026 
rs410150 18 40066006 T C 0.80 -0.047 0.019 
rs17596995 18 53166594 A G 0.20 -0.049 0.019 
rs1517037 18 56878274 T C 0.19 -0.093 0.020 
rs6567160 18 57829135 C T 0.23 0.097 0.018 
rs74625348 18 60846430 C G 0.23 -0.044 0.019 
rs12963820 18 63426213 A T 0.27 0.034 0.017 
rs7240767 18 7070642 C T 0.39 0.063 0.016 
rs6565922 18 74558999 T C 0.38 0.078 0.016 
rs9384 19 13010643 T G 0.38 -0.107 0.016 
rs10404726 19 18834514 T C 0.47 -0.035 0.015 
rs58542926 19 19379549 T C 0.08 0.139 0.029 
rs924150 19 31829903 C A 0.39 -0.087 0.016 
rs4805881 19 33896432 C A 0.67 -0.077 0.016 
rs429358 19 45411941 C T 0.16 -0.142 0.021 
rs8107527 19 46158417 A G 0.28 0.105 0.017 
rs9304665 19 47602577 A T 0.77 0.103 0.018 
rs2115107 19 7968168 A G 0.38 0.069 0.016 
rs116843064 19 8429323 A G 0.02 -0.150 0.055 
rs7554251 1 11317932 C T 0.73 0.036 0.017 
rs1127215 1 117532790 T C 0.42 -0.065 0.016 
rs66464442 1 118171801 A C 0.32 0.121 0.016 
rs1493694 1 120526982 T C 0.11 0.146 0.025 
rs145904381 1 151017991 C T 0.01 -0.266 0.071 
rs2297607 1 154320942 G A 0.24 0.051 0.018 
rs6696888 1 155508882 A G 0.68 -0.048 0.016 
rs7546252 1 172368310 G A 0.56 -0.092 0.015 
rs539515 1 177889025 C A 0.21 0.049 0.019 
rs2816177 1 179248952 G A 0.41 0.049 0.016 
rs41304257 1 201849926 G A 0.28 -0.042 0.017 
rs61817176 1 206621028 C A 0.52 -0.074 0.015 
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rs340874 1 214159256 C T 0.57 0.166 0.015 
rs1337101 1 219726100 T G 0.32 -0.095 0.016 
rs348330 1 229672955 A G 0.63 -0.119 0.016 
rs10925635 1 235573486 C A 0.64 0.046 0.016 
rs17261915 1 26756856 C T 0.25 0.074 0.018 
rs3753693 1 29060898 T C 0.41 -0.066 0.016 
rs61779284 1 39855177 A G 0.21 0.130 0.019 
rs79090772 1 51209148 C T 0.09 -0.219 0.027 
rs2269247 1 64107284 T C 0.18 -0.056 0.020 
rs11583755 1 6672729 C A 0.36 0.107 0.016 
rs2613499 1 72751552 G A 0.19 -0.052 0.019 
rs10159026 1 96404462 T C 0.25 -0.062 0.018 
rs6137042 20 2100095 A G 0.20 -0.050 0.019 
rs7274134 20 22428284 T C 0.25 -0.062 0.018 
rs6059662 20 32675727 G A 0.65 0.037 0.016 
rs2038457 20 42239145 G A 0.81 0.041 0.020 
rs12625671 20 42994812 C T 0.11 0.118 0.025 
rs6066138 20 45594711 A G 0.28 -0.135 0.017 
rs6021276 20 50155386 C T 0.64 -0.074 0.016 
rs865034 20 51261615 C T 0.66 0.040 0.016 
rs4810145 20 57396495 C T 0.52 0.068 0.015 
rs6011155 20 62450664 C T 0.37 -0.074 0.016 
rs2240716 22 19969696 T C 0.30 0.074 0.017 
rs56392746 22 30451688 A G 0.09 -0.138 0.026 
rs75307421 22 32203334 A G 0.02 0.151 0.061 
rs138771 22 35705359 G A 0.81 -0.055 0.020 
rs1801645 22 50356850 T C 0.74 -0.059 0.018 
rs34506349 2 100598726 A G 0.04 -0.099 0.038 
rs79950062 2 111940612 C T 0.13 -0.053 0.023 
rs9308614 2 121337196 G A 0.15 -0.090 0.022 
rs6716394 2 146350724 A G 0.54 -0.045 0.015 
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rs10184004 2 165508389 T C 0.41 -0.115 0.016 
rs11680058 2 16574669 A G 0.87 0.104 0.025 
rs13406280 2 166610827 T C 0.49 -0.047 0.015 
rs72917531 2 175238176 A C 0.19 -0.078 0.020 
rs36051007 2 179545859 T C 0.32 -0.035 0.017 
rs67383253 2 181570394 C T 0.37 -0.035 0.016 
rs6712905 2 196952010 C T 0.26 0.048 0.018 
rs4482463 2 205375909 A C 0.92 -0.063 0.029 
rs34329895 2 208870017 G A 0.60 -0.063 0.016 
rs2943650 2 227105921 T C 0.65 0.143 0.016 
rs13415288 2 228971884 C T 0.34 0.059 0.016 
rs34339006 2 234271522 T C 0.39 0.092 0.016 
rs1260326 2 27730940 C T 0.61 0.156 0.016 
rs77165542 2 430975 T C 0.04 -0.155 0.042 
rs921069 2 43206922 G A 0.58 -0.038 0.016 
rs76675804 2 43611883 C T 0.10 -0.311 0.026 
rs10193538 2 58981064 T G 0.61 0.072 0.016 
rs243018 2 60586707 G C 0.45 0.088 0.016 
rs114213622 2 65243284 T G 0.01 -0.303 0.080 
rs10188334 2 653874 T C 0.17 -0.087 0.020 
rs12185610 2 65661468 C A 0.41 -0.063 0.016 
rs4671799 2 67622243 G A 0.68 -0.036 0.016 
rs4832290 2 86707504 C T 0.77 -0.053 0.018 
rs17036126 3 12287863 T C 0.13 0.127 0.023 
rs11708067 3 123065778 G A 0.25 -0.262 0.018 
rs17036160 3 12329783 T C 0.12 -0.088 0.024 
rs9873519 3 124921457 T C 0.53 0.097 0.015 
rs1224997 3 131631201 T C 0.28 0.072 0.017 
rs667920 3 136069472 T G 0.77 0.038 0.018 
rs9289556 3 138033181 T C 0.73 -0.077 0.017 
rs56243018 3 141101839 C A 0.05 -0.214 0.036 
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rs7633673 3 152084243 A G 0.41 -0.086 0.016 
rs11706810 3 160159921 C T 0.48 -0.106 0.015 
rs13099581 3 168226052 T C 0.14 -0.060 0.022 
rs8192675 3 170724883 C T 0.29 -0.188 0.017 
rs6444036 3 184901216 T G 0.16 0.041 0.021 
rs9859406 3 185534482 A G 0.31 0.167 0.017 
rs2041965 3 186648411 T C 0.34 -0.083 0.016 
rs6777684 3 187741842 G A 0.61 0.134 0.016 
rs13094957 3 23457080 C T 0.20 -0.131 0.019 
rs1470560 3 35670150 A G 0.37 0.037 0.016 
rs2624847 3 50174197 T G 0.74 -0.084 0.017 
rs13434089 3 63948566 C T 0.12 -0.082 0.024 
rs9870517 3 64708600 C A 0.40 -0.096 0.016 
rs1374915 3 71668037 C T 0.42 -0.036 0.016 
rs1523766 3 77670448 G A 0.50 -0.031 0.015 
rs978444 3 93981060 T G 0.55 -0.057 0.015 
rs3872707 3 9514016 A G 0.12 0.049 0.023 
rs7659468 4 103895317 G T 0.49 -0.103 0.015 
rs11728350 4 106078097 G A 0.13 0.110 0.023 
rs77141743 4 121774048 A G 0.16 0.045 0.021 
rs730831 4 1240299 G T 0.04 -0.123 0.041 
rs2604918 4 140879929 T G 0.33 -0.063 0.016 
rs2125799 4 156697784 C T 0.33 0.060 0.016 
rs28819812 4 157652753 A C 0.32 -0.060 0.016 
rs4865436 4 1788130 G C 0.29 0.050 0.018 
rs2169033 4 18044357 T C 0.68 0.081 0.017 
rs55691245 4 185716100 A G 0.14 -0.160 0.022 
rs7664347 4 20265535 C T 0.64 -0.040 0.016 
rs10938398 4 45186139 A G 0.43 0.040 0.016 
rs1996617 4 52798624 C T 0.29 0.101 0.017 
rs114447556 4 53207093 T C 0.08 0.080 0.029 




 http://ahajournals.org by on July 9, 2021
rs73222806 4 753840 G C 0.05 0.098 0.035 
rs6835992 4 76496817 G A 0.69 0.066 0.017 
rs993380 4 83584496 G A 0.67 -0.059 0.016 
rs28408270 4 95114572 T G 0.47 -0.050 0.015 
rs1961224 4 95999825 G A 0.35 -0.065 0.016 
rs141146025 5 101966291 A C 0.02 0.129 0.058 
rs75432112 5 102586407 A G 0.05 0.195 0.036 
rs329118 5 133861663 T C 0.42 0.041 0.016 
rs111686785 5 14738965 G A 0.03 0.182 0.044 
rs72734782 5 14789003 G A 0.21 0.066 0.019 
rs12514030 5 14810110 G T 0.12 -0.103 0.023 
rs1650505 5 158029734 A G 0.21 0.060 0.019 
rs4343858 5 176679407 A G 0.23 -0.042 0.018 
rs138373837 5 36219710 T C 0.02 0.101 0.050 
rs62366821 5 44875449 G A 0.49 -0.055 0.015 
rs10067659 5 52084365 C G 0.79 -0.081 0.019 
rs4865796 5 53272664 A G 0.69 0.049 0.017 
rs464605 5 55807370 T C 0.75 0.080 0.019 
rs34341 5 74934009 T A 0.58 0.073 0.016 
rs7732130 5 76435004 A G 0.68 -0.132 0.016 
rs6870983 5 87697533 T C 0.21 -0.067 0.019 
rs34483452 5 87986314 A C 0.14 0.077 0.023 
rs7752666 6 107445266 T C 0.32 -0.035 0.017 
rs80196932 6 117996631 C T 0.16 -0.064 0.021 
rs11759026 6 126792095 G A 0.23 0.136 0.018 
rs2876354 6 137295352 T C 0.47 -0.083 0.016 
rs7742292 6 138864489 C T 0.40 0.041 0.016 
rs2982521 6 139835329 T A 0.63 -0.110 0.016 
rs9390022 6 143056556 C T 0.38 -0.042 0.016 
rs1538247 6 153395344 C T 0.30 0.093 0.017 
rs2179168 6 15477030 A G 0.80 0.046 0.019 
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rs4709746 6 164133001 T C 0.13 -0.050 0.023 
rs7774074 6 20517130 A C 0.21 0.039 0.019 
rs35261542 6 20675792 A C 0.26 0.268 0.017 
rs3117189 6 32033944 G A 0.85 0.281 0.021 
rs2780215 6 34236973 G A 0.07 -0.110 0.033 
rs7748962 6 43759927 A G 0.77 0.113 0.018 
rs9472139 6 43813711 C G 0.29 0.065 0.017 
rs3798519 6 50788778 C A 0.18 0.107 0.020 
rs9370243 6 53789830 T G 0.08 0.079 0.028 
rs9449295 6 64163807 C T 0.54 0.036 0.015 
rs9379084 6 7231843 A G 0.12 -0.198 0.025 
rs187653072 7 102976385 C T 0.03 0.134 0.044 
rs73184014 7 104516274 G A 0.22 -0.053 0.019 
rs6976111 7 117495667 A C 0.30 0.074 0.017 
rs13237518 7 12269593 A C 0.41 0.048 0.016 
rs3996350 7 130427057 C G 0.50 -0.086 0.015 
rs60251368 7 140522073 G A 0.06 0.096 0.034 
rs4252505 7 142607301 G A 0.06 0.070 0.031 
rs17168486 7 14898282 T C 0.17 0.162 0.020 
rs4725959 7 150534741 G A 0.22 0.042 0.019 
rs10228796 7 15064190 G C 0.55 0.160 0.015 
rs6946660 7 156948648 C T 0.35 -0.107 0.016 
rs11762413 7 2090387 G C 0.25 -0.085 0.018 
rs2188848 7 23884697 G A 0.20 -0.055 0.019 
rs860262 7 28194397 A C 0.50 -0.158 0.015 
rs917195 7 30728452 T C 0.23 -0.073 0.018 
rs730497 7 44223721 A G 0.18 0.445 0.020 
rs73121277 7 50577968 C T 0.28 0.084 0.017 
rs6975279 7 69649683 A C 0.26 0.101 0.018 
rs6956980 7 89803634 C T 0.53 0.083 0.015 
rs7834323 8 10671984 C T 0.29 -0.074 0.017 
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rs13266634 8 118184783 T C 0.31 -0.277 0.017 
rs12056338 8 12643055 T G 0.42 0.050 0.016 
rs17772814 8 128711742 A G 0.08 -0.099 0.029 
rs1561927 8 129568078 T C 0.73 -0.048 0.017 
rs35753840 8 14148990 C A 0.39 0.054 0.016 
rs13268508 8 145525277 T C 0.38 0.087 0.016 
rs2953845 8 145972950 T C 0.55 0.042 0.015 
rs6558173 8 22492103 T G 0.35 0.039 0.016 
rs2725370 8 30852826 C T 0.70 -0.049 0.017 
rs57735787 8 34438332 G A 0.25 -0.042 0.018 
rs13262861 8 41508577 A C 0.17 -0.121 0.021 
rs7813865 8 57506937 C T 0.29 0.041 0.017 
rs10101067 8 72407374 C G 0.08 0.092 0.029 
rs28792187 8 74568099 G A 0.07 0.123 0.030 
rs1895874 8 95675372 A G 0.50 0.048 0.015 
rs10808671 8 95967372 G A 0.53 -0.073 0.015 
rs60384372 8 9974584 G A 0.47 -0.056 0.015 
rs1567353 9 1033773 G C 0.31 0.035 0.017 
rs10119430 9 111938268 A G 0.79 -0.054 0.019 
rs1431819 9 116943357 G A 0.70 0.038 0.017 
rs10818763 9 125689694 T C 0.13 -0.108 0.023 
rs10739629 9 126093422 T C 0.51 -0.036 0.015 
rs529565 9 136149500 C T 0.32 0.164 0.017 
rs28642213 9 139248082 G A 0.75 0.169 0.018 
rs12380322 9 19074538 G A 0.39 0.051 0.016 
rs10965247 9 22132729 G A 0.18 -0.302 0.020 
rs7018475 9 22137685 G T 0.26 0.178 0.018 
rs11788619 9 22258082 T A 0.03 -0.134 0.048 
rs2150854 9 28411949 T G 0.33 0.072 0.016 
rs4237150 9 4290085 C G 0.40 0.091 0.016 
rs67269808 9 81907986 G A 0.06 -0.130 0.032 
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rs7023781 9 96447178 T C 0.27 0.058 0.017 
rs10993072 9 96915002 T C 0.32 0.083 0.016 
rs28496034 9 98278332 G C 0.33 -0.057 0.016 
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Table S5. Genetic proxies for glycemic control by any mechanism, and estimates for their association with 
glycated hemoglobin (for the outcome of left ventricular ejection fraction).  
 





EAF Beta SE 
rs2482506 10 104563743 G C 0.25 -0.053 0.018 
rs7090695 10 112801213 C G 0.80 0.060 0.019 
rs11196174 10 114734096 G A 0.29 0.252 0.017 
rs4918790 10 114830254 A G 0.91 -0.117 0.028 
rs4752351 10 121685016 C T 0.20 0.087 0.019 
rs11257655 10 12307894 T C 0.21 0.219 0.019 
rs946859 10 13565429 A G 0.47 -0.075 0.015 
rs3122231 10 44027356 C T 0.65 0.050 0.016 
rs949693 10 70354574 A G 0.61 -0.050 0.016 
rs11592899 10 71333783 A G 0.34 -0.055 0.016 
rs2812535 10 71456857 A G 0.62 0.069 0.016 
rs697239 10 80947438 C T 0.46 -0.105 0.015 
rs11201992 10 88117318 A C 0.46 -0.038 0.015 
rs1111875 10 94462882 T C 0.41 -0.181 0.016 
rs66536955 10 94737667 C T 0.26 0.044 0.017 
rs34041345 10 99174580 G T 0.26 0.060 0.018 
rs529623 11 117693255 C T 0.52 -0.059 0.015 
rs10893830 11 128044159 T C 0.13 -0.058 0.023 
rs10750397 11 128234144 G A 0.72 -0.040 0.017 
rs67232546 11 128398938 T C 0.21 0.067 0.019 
rs757110 11 17418477 A C 0.64 -0.112 0.016 
rs11042987 11 2201059 A C 0.58 -0.034 0.016 
rs2283167 11 2580063 A G 0.14 -0.055 0.023 
rs231362 11 2691471 G A 0.52 0.120 0.015 
rs10767659 11 27686196 T G 0.67 -0.041 0.016 
rs60808706 11 2857233 A G 0.05 -0.227 0.035 
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rs74673753 11 32623621 T A 0.06 -0.106 0.033 
rs2956092 11 34908780 C T 0.69 -0.059 0.017 
rs3816605 11 47857253 C T 0.45 -0.080 0.015 
rs7483027 11 58128015 C T 0.38 -0.061 0.016 
rs174541 11 61565908 C T 0.36 -0.098 0.016 
rs12789028 11 65326154 A G 0.20 0.084 0.019 
rs11602873 11 72460762 T A 0.16 -0.187 0.021 
rs11236524 11 75464344 C T 0.09 0.069 0.027 
rs2513505 11 76230357 A C 0.60 0.033 0.016 
rs12802861 11 8387806 T C 0.28 -0.052 0.017 
rs10830963 11 92708710 G C 0.28 0.297 0.017 
rs3020069 11 93057087 A G 0.68 0.093 0.016 
rs1426371 12 108629780 A G 0.26 -0.074 0.018 
rs79310463 12 118406696 T C 0.13 0.104 0.023 
rs56348580 12 121432117 C G 0.31 -0.037 0.017 
rs7975763 12 123604053 T C 0.20 -0.057 0.019 
rs2066827 12 12871099 G T 0.23 0.102 0.018 
rs11614914 12 133070294 T C 0.33 0.078 0.016 
rs12828318 12 133766122 G A 0.18 -0.057 0.020 
rs10841886 12 21864377 C T 0.23 -0.082 0.018 
rs1480029 12 26356032 A G 0.46 0.042 0.015 
rs3751239 12 27963676 G C 0.20 -0.160 0.019 
rs7298690 12 4313438 C T 0.21 0.060 0.019 
rs3217893 12 4403876 T C 0.09 -0.171 0.030 
rs2732469 12 48712932 A T 0.43 -0.258 0.015 
rs61937817 12 57212823 G T 0.11 0.060 0.024 
rs11173646 12 61250814 T A 0.82 -0.046 0.020 
rs2257883 12 66216162 A G 0.13 0.150 0.023 
rs12371967 12 66346714 C T 0.17 -0.043 0.020 
rs10879261 12 71520761 G T 0.41 0.068 0.016 
rs11108094 12 95928113 A C 0.07 0.099 0.030 
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rs9587811 13 109946882 A C 0.41 -0.056 0.016 
rs314879 13 23309382 T C 0.79 -0.069 0.019 
rs34584161 13 26776999 G A 0.24 -0.063 0.018 
rs380854 13 33574631 A G 0.58 -0.058 0.016 
rs9316500 13 51094114 G T 0.29 -0.067 0.017 
rs7991679 13 58691107 A T 0.16 -0.081 0.021 
rs1215451 13 80715893 A G 0.29 -0.131 0.017 
rs112324411 14 101258584 T C 0.07 -0.101 0.032 
rs2295388 14 101309759 A G 0.22 -0.073 0.019 
rs4906272 14 103376031 T C 0.16 0.046 0.021 
rs12883788 14 33303540 T C 0.46 0.060 0.015 
rs7147483 14 38804675 C T 0.25 -0.158 0.018 
rs723355 14 47304091 A G 0.50 -0.034 0.015 
rs4902002 14 61229411 A G 0.71 -0.034 0.017 
rs242105 14 69459229 C A 0.28 0.062 0.017 
rs7156625 14 79942647 A G 0.22 0.037 0.019 
rs8010382 14 91963722 G A 0.41 0.046 0.016 
rs8043085 15 38828140 T G 0.23 0.071 0.018 
rs11856877 15 40620560 G A 0.11 0.071 0.024 
rs1473781 15 41818917 A G 0.35 0.067 0.016 
rs71472935 15 52565725 C G 0.11 -0.145 0.025 
rs7163757 15 62391608 T C 0.43 -0.042 0.015 
rs7178762 15 63871292 T C 0.55 -0.057 0.015 
rs9479 15 74328576 G A 0.49 0.052 0.015 
rs8033589 15 75596685 A G 0.76 0.058 0.018 
rs12910361 15 77782335 G A 0.71 0.161 0.017 
rs893617 15 90381278 T C 0.72 -0.136 0.017 
rs2290202 15 91512267 T G 0.13 0.085 0.023 
rs9927842 16 15153717 C T 0.84 -0.056 0.021 
rs8056890 16 28897452 A G 0.36 0.105 0.016 
rs8054556 16 29958216 A G 0.47 0.077 0.015 
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rs8061528 16 3656482 T C 0.21 0.092 0.019 
rs2024449 16 53494617 C T 0.44 -0.056 0.015 
rs1421085 16 53800954 C T 0.40 0.154 0.016 
rs56125990 16 69742387 G A 0.15 0.065 0.021 
rs4788815 16 71634811 T A 0.66 0.056 0.016 
rs72802365 16 75246035 C G 0.08 -0.163 0.029 
rs2966117 16 81599271 T G 0.48 0.059 0.015 
rs11117364 16 88132199 G A 0.68 0.066 0.017 
rs9937296 16 88554480 C T 0.86 0.069 0.023 
rs66461358 16 89535257 C T 0.15 0.060 0.021 
rs12934854 16 950028 A G 0.17 0.043 0.020 
rs925095 17 17344653 T C 0.39 -0.075 0.016 
rs2297508 17 17715317 G C 0.65 -0.150 0.016 
rs9913225 17 27570622 A G 0.58 -0.075 0.016 
rs1109442 17 34862220 C T 0.47 0.071 0.015 
rs3110641 17 36047417 G A 0.78 0.091 0.019 
rs11651755 17 36099840 T C 0.51 -0.124 0.015 
rs3786017 17 3830340 C T 0.11 0.054 0.025 
rs8071043 17 3988451 C T 0.33 0.066 0.016 
rs1905339 17 40582296 C T 0.34 0.097 0.016 
rs35895680 17 47060322 A C 0.33 -0.089 0.016 
rs366577 17 4854480 T C 0.60 -0.051 0.016 
rs57767539 17 62203059 A G 0.07 0.136 0.031 
rs11658220 17 65646092 A G 0.10 0.100 0.025 
rs12603589 17 65825248 C T 0.19 0.103 0.020 
rs7224711 17 76772288 T C 0.53 -0.069 0.015 
rs303760 18 21083738 T C 0.35 0.052 0.016 
rs16965062 18 31581247 T C 0.43 0.034 0.015 
rs7227272 18 36746623 A G 0.10 -0.062 0.026 
rs410150 18 40066006 T C 0.80 -0.047 0.019 
rs17596995 18 53166594 A G 0.20 -0.049 0.019 
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rs6567160 18 57829135 C T 0.23 0.097 0.018 
rs74625348 18 60846430 C G 0.23 -0.044 0.019 
rs12963820 18 63426213 A T 0.27 0.034 0.017 
rs7240767 18 7070642 C T 0.39 0.063 0.016 
rs6565922 18 74558999 T C 0.38 0.078 0.016 
rs9384 19 13010643 T G 0.38 -0.107 0.016 
rs10404726 19 18834514 T C 0.47 -0.035 0.015 
rs58542926 19 19379549 T C 0.08 0.139 0.029 
rs924150 19 31829903 C A 0.39 -0.087 0.016 
rs4805881 19 33896432 C A 0.67 -0.077 0.016 
rs429358 19 45411941 C T 0.16 -0.142 0.021 
rs8107527 19 46158417 A G 0.28 0.105 0.017 
rs9304665 19 47602577 A T 0.77 0.103 0.018 
rs2115107 19 7968168 A G 0.38 0.069 0.016 
rs7554251 1 11317932 C T 0.73 0.036 0.017 
rs1127215 1 117532790 T C 0.42 -0.065 0.016 
rs66464442 1 118171801 A C 0.32 0.121 0.016 
rs1493694 1 120526982 T C 0.11 0.146 0.025 
rs115983556 1 149873582 C A 0.08 -0.153 0.028 
rs1194592 1 154324384 G C 0.44 -0.044 0.015 
rs3020781 1 155269776 G A 0.27 0.086 0.017 
rs7546252 1 172368310 G A 0.56 -0.092 0.015 
rs539515 1 177889025 C A 0.21 0.049 0.019 
rs2816177 1 179248952 G A 0.41 0.049 0.016 
rs41304257 1 201849926 G A 0.28 -0.042 0.017 
rs61817176 1 206621028 C A 0.52 -0.074 0.015 
rs10916780 1 20707153 G A 0.20 -0.045 0.019 
rs340874 1 214159256 C T 0.57 0.166 0.015 
rs1337101 1 219726100 T G 0.32 -0.095 0.016 
rs348330 1 229672955 A G 0.63 -0.119 0.016 
rs10925635 1 235573486 C A 0.64 0.046 0.016 
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rs3753693 1 29060898 T C 0.41 -0.066 0.016 
rs61779284 1 39855177 A G 0.21 0.130 0.019 
rs79090772 1 51209148 C T 0.09 -0.219 0.027 
rs2269247 1 64107284 T C 0.18 -0.056 0.020 
rs11583755 1 6672729 C A 0.36 0.107 0.016 
rs2613499 1 72751552 G A 0.19 -0.052 0.019 
rs10159026 1 96404462 T C 0.25 -0.062 0.018 
rs6137042 20 2100095 A G 0.20 -0.050 0.019 
rs7274134 20 22428284 T C 0.25 -0.062 0.018 
rs6059662 20 32675727 G A 0.65 0.037 0.016 
rs2038457 20 42239145 G A 0.81 0.041 0.020 
rs12625671 20 42994812 C T 0.11 0.118 0.025 
rs6066138 20 45594711 A G 0.28 -0.135 0.017 
rs6021276 20 50155386 C T 0.64 -0.074 0.016 
rs865034 20 51261615 C T 0.66 0.040 0.016 
rs4810145 20 57396495 C T 0.52 0.068 0.015 
rs6011155 20 62450664 C T 0.37 -0.074 0.016 
rs2240716 22 19969696 T C 0.30 0.074 0.017 
rs56392746 22 30451688 A G 0.09 -0.138 0.026 
rs138771 22 35705359 G A 0.81 -0.055 0.020 
rs1801645 22 50356850 T C 0.74 -0.059 0.018 
rs79950062 2 111940612 C T 0.13 -0.053 0.023 
rs9308614 2 121337196 G A 0.15 -0.090 0.022 
rs6716394 2 146350724 A G 0.54 -0.045 0.015 
rs4668483 2 16231732 G A 0.68 -0.040 0.016 
rs10184004 2 165508389 T C 0.41 -0.115 0.016 
rs11680058 2 16574669 A G 0.87 0.104 0.025 
rs13406280 2 166610827 T C 0.49 -0.047 0.015 
rs72917531 2 175238176 A C 0.19 -0.078 0.020 
rs36051007 2 179545859 T C 0.32 -0.035 0.017 
rs67383253 2 181570394 C T 0.37 -0.035 0.016 
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rs4482463 2 205375909 A C 0.92 -0.063 0.029 
rs34329895 2 208870017 G A 0.60 -0.063 0.016 
rs2943650 2 227105921 T C 0.65 0.143 0.016 
rs13415288 2 228971884 C T 0.34 0.059 0.016 
rs34339006 2 234271522 T C 0.39 0.092 0.016 
rs1260326 2 27730940 C T 0.61 0.156 0.016 
rs921069 2 43206922 G A 0.58 -0.038 0.016 
rs76675804 2 43611883 C T 0.10 -0.311 0.026 
rs10193538 2 58981064 T G 0.61 0.072 0.016 
rs243018 2 60586707 G C 0.45 0.088 0.016 
rs10188334 2 653874 T C 0.17 -0.087 0.020 
rs12185610 2 65661468 C A 0.41 -0.063 0.016 
rs4671799 2 67622243 G A 0.68 -0.036 0.016 
rs4832290 2 86707504 C T 0.77 -0.053 0.018 
rs17036126 3 12287863 T C 0.13 0.127 0.023 
rs11708067 3 123065778 G A 0.25 -0.262 0.018 
rs17036160 3 12329783 T C 0.12 -0.088 0.024 
rs9873519 3 124921457 T C 0.53 0.097 0.015 
rs1225004 3 131626991 C T 0.28 0.071 0.017 
rs667920 3 136069472 T G 0.77 0.038 0.018 
rs6766859 3 138055136 T C 0.63 -0.091 0.016 
rs34573045 3 149196752 G C 0.43 0.049 0.015 
rs7633673 3 152084243 A G 0.41 -0.086 0.016 
rs11706810 3 160159921 C T 0.48 -0.106 0.015 
rs13099581 3 168226052 T C 0.14 -0.060 0.022 
rs8192675 3 170724883 C T 0.29 -0.188 0.017 
rs6444036 3 184901216 T G 0.16 0.041 0.021 
rs9859406 3 185534482 A G 0.31 0.167 0.017 
rs2041965 3 186648411 T C 0.34 -0.083 0.016 
rs6777684 3 187741842 G A 0.61 0.134 0.016 
rs13094957 3 23457080 C T 0.20 -0.131 0.019 
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rs2624847 3 50174197 T G 0.74 -0.084 0.017 
rs13434089 3 63948566 C T 0.12 -0.082 0.024 
rs9870517 3 64708600 C A 0.40 -0.096 0.016 
rs1374915 3 71668037 C T 0.42 -0.036 0.016 
rs1523766 3 77670448 G A 0.50 -0.031 0.015 
rs978444 3 93981060 T G 0.55 -0.057 0.015 
rs3872707 3 9514016 A G 0.12 0.049 0.023 
rs7659468 4 103895317 G T 0.49 -0.103 0.015 
rs11728350 4 106078097 G A 0.13 0.110 0.023 
rs77141743 4 121774048 A G 0.16 0.045 0.021 
rs2604918 4 140879929 T G 0.33 -0.063 0.016 
rs2125799 4 156697784 C T 0.33 0.060 0.016 
rs28819812 4 157652753 A C 0.32 -0.060 0.016 
rs4865436 4 1788130 G C 0.29 0.050 0.018 
rs2169033 4 18044357 T C 0.68 0.081 0.017 
rs55691245 4 185716100 A G 0.14 -0.160 0.022 
rs7664347 4 20265535 C T 0.64 -0.040 0.016 
rs10938398 4 45186139 A G 0.43 0.040 0.016 
rs1996617 4 52798624 C T 0.29 0.101 0.017 
rs114447556 4 53207093 T C 0.08 0.080 0.029 
rs10937721 4 6306763 C G 0.59 0.142 0.016 
rs75724417 4 757921 T C 0.05 0.089 0.035 
rs6835992 4 76496817 G A 0.69 0.066 0.017 
rs993380 4 83584496 G A 0.67 -0.059 0.016 
rs28408270 4 95114572 T G 0.47 -0.050 0.015 
rs1961224 4 95999825 G A 0.35 -0.065 0.016 
rs116782923 5 102331465 T A 0.05 0.197 0.034 
rs329118 5 133861663 T C 0.42 0.041 0.016 
rs9312873 5 14777799 G A 0.10 -0.160 0.026 
rs1650505 5 158029734 A G 0.21 0.060 0.019 
rs4343858 5 176679407 A G 0.23 -0.042 0.018 
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rs10067659 5 52084365 C G 0.79 -0.081 0.019 
rs4865796 5 53272664 A G 0.69 0.049 0.017 
rs464605 5 55807370 T C 0.75 0.080 0.019 
rs34341 5 74934009 T A 0.58 0.073 0.016 
rs7732130 5 76435004 A G 0.68 -0.132 0.016 
rs6870983 5 87697533 T C 0.21 -0.067 0.019 
rs34483452 5 87986314 A C 0.14 0.077 0.023 
rs7752666 6 107445266 T C 0.32 -0.035 0.017 
rs80196932 6 117996631 C T 0.16 -0.064 0.021 
rs11759026 6 126792095 G A 0.23 0.136 0.018 
rs2876354 6 137295352 T C 0.47 -0.083 0.016 
rs7742292 6 138864489 C T 0.40 0.041 0.016 
rs2982521 6 139835329 T A 0.63 -0.110 0.016 
rs9390022 6 143056556 C T 0.38 -0.042 0.016 
rs1538247 6 153395344 C T 0.30 0.093 0.017 
rs2179168 6 15477030 A G 0.80 0.046 0.019 
rs501470 6 160770918 G T 0.47 -0.089 0.015 
rs4709746 6 164133001 T C 0.13 -0.050 0.023 
rs7774074 6 20517130 A C 0.21 0.039 0.019 
rs35261542 6 20675792 A C 0.26 0.268 0.017 
rs3117189 6 32033944 G A 0.85 0.281 0.021 
rs2780215 6 34236973 G A 0.07 -0.110 0.033 
rs7748962 6 43759927 A G 0.77 0.113 0.018 
rs9472139 6 43813711 C G 0.29 0.065 0.017 
rs3798519 6 50788778 C A 0.18 0.107 0.020 
rs9370243 6 53789830 T G 0.08 0.079 0.028 
rs9449295 6 64163807 C T 0.54 0.036 0.015 
rs9379084 6 7231843 A G 0.12 -0.198 0.025 
rs62482399 7 102972707 T C 0.09 0.087 0.027 
rs73184014 7 104516274 G A 0.22 -0.053 0.019 
rs6976111 7 117495667 A C 0.30 0.074 0.017 
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rs3996350 7 130427057 C G 0.50 -0.086 0.015 
rs60251368 7 140522073 G A 0.06 0.096 0.034 
rs4252505 7 142607301 G A 0.06 0.070 0.031 
rs17168486 7 14898282 T C 0.17 0.162 0.020 
rs4725959 7 150534741 G A 0.22 0.042 0.019 
rs10228796 7 15064190 G C 0.55 0.160 0.015 
rs6946660 7 156948648 C T 0.35 -0.107 0.016 
rs11762413 7 2090387 G C 0.25 -0.085 0.018 
rs2188848 7 23884697 G A 0.20 -0.055 0.019 
rs860262 7 28194397 A C 0.50 -0.158 0.015 
rs917195 7 30728452 T C 0.23 -0.073 0.018 
rs730497 7 44223721 A G 0.18 0.445 0.020 
rs73121277 7 50577968 C T 0.28 0.084 0.017 
rs6975279 7 69649683 A C 0.26 0.101 0.018 
rs6956980 7 89803634 C T 0.53 0.083 0.015 
rs7834323 8 10671984 C T 0.29 -0.074 0.017 
rs727582 8 116650468 G A 0.34 -0.093 0.016 
rs13266634 8 118184783 T C 0.31 -0.277 0.017 
rs12056338 8 12643055 T G 0.42 0.050 0.016 
rs17772814 8 128711742 A G 0.08 -0.099 0.029 
rs1561927 8 129568078 T C 0.73 -0.048 0.017 
rs35753840 8 14148990 C A 0.39 0.054 0.016 
rs13268508 8 145525277 T C 0.38 0.087 0.016 
rs2953845 8 145972950 T C 0.55 0.042 0.015 
rs6558173 8 22492103 T G 0.35 0.039 0.016 
rs2725370 8 30852826 C T 0.70 -0.049 0.017 
rs57735787 8 34438332 G A 0.25 -0.042 0.018 
rs13262861 8 41508577 A C 0.17 -0.121 0.021 
rs7813865 8 57506937 C T 0.29 0.041 0.017 
rs10101067 8 72407374 C G 0.08 0.092 0.029 
rs28792187 8 74568099 G A 0.07 0.123 0.030 
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rs10808671 8 95967372 G A 0.53 -0.073 0.015 
rs60384372 8 9974584 G A 0.47 -0.056 0.015 
rs1567353 9 1033773 G C 0.31 0.035 0.017 
rs10119430 9 111938268 A G 0.79 -0.054 0.019 
rs1431819 9 116943357 G A 0.70 0.038 0.017 
rs10818763 9 125689694 T C 0.13 -0.108 0.023 
rs10739629 9 126093422 T C 0.51 -0.036 0.015 
rs529565 9 136149500 C T 0.32 0.164 0.017 
rs28642213 9 139248082 G A 0.75 0.169 0.018 
rs12380322 9 19074538 G A 0.39 0.051 0.016 
rs10965247 9 22132729 G A 0.18 -0.302 0.020 
rs7018475 9 22137685 G T 0.26 0.178 0.018 
rs2150854 9 28411949 T G 0.33 0.072 0.016 
rs4237150 9 4290085 C G 0.40 0.091 0.016 
rs67269808 9 81907986 G A 0.06 -0.130 0.032 
rs2796441 9 84308948 A G 0.42 -0.096 0.016 
rs7023781 9 96447178 T C 0.27 0.058 0.017 
rs10993072 9 96915002 T C 0.32 0.083 0.016 
rs28496034 9 98278332 G C 0.33 -0.057 0.016 
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Table S6. Weighted median sensitivity analyses for the association of genetically proxied glucagon-like peptide 
receptor (GLP1R) agonism and glycemic control more generally with heart failure (HF; 47,309 cases / 930,014 











SD: standard deviation; SNP: single-nucleotide polymorphism. 
 
  
Exposure Outcome N SNPs Effect units Effect P value 
GLP1R HF 3 Odds ratio 0.77 [0.62, 0.96] 0.02 
Glycemia HF 350 Odds ratio 0.98 [0.96, 1.00] 0.04 
GLP1R LVEF 3 SD change in LVEF 0.18 [-0.07, 0.42] 0.16 
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Figure S1. Scatter plot displaying genetic associations of the GLP1R genetic proxies with glycated hemoglobin 




Each point represents a single genetic variant, with vertical and horizontal lines representing standard errors. The slope of 
the blue diagonal line represents the inverse-variance weighted Mendelian randomization estimate. The P value for the 
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Figure S2. Scatter plot displaying genetic associations of the GLP1R genetic proxies with type 2 diabetes liability 




Each point represents a single genetic variant, with vertical and horizontal lines representing standard errors. The slope of 
the blue diagonal line represents the inverse-variance weighted Mendelian randomization estimate. The P value for the 
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Figure S3. Scatter plot displaying genetic associations of the GLP1R genetic proxies with glycated hemoglobin 
(mmol/mol, x-axis) and left ventricular ejection fraction (standard deviation units, y-axis).  
 
 
Each point represents a single genetic variant, with vertical and horizontal lines representing standard errors. The slope of 
the blue diagonal line represents the inverse-variance weighted Mendelian randomization estimate. The P value for the 
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Figure S4. Scatter plot displaying genetic associations of the glycemia genetic proxies with glycated hemoglobin 
(mmol/mol, x-axis) and heart failure risk (log-odds, y-axis).  
 
 
Each point represents a single genetic variant, with vertical and horizontal lines representing standard errors. The slope of 
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Figure S5. Scatter plot displaying genetic associations of the glycemia genetic proxies with glycated hemoglobin 




Each point represents a single genetic variant, with vertical and horizontal lines representing standard errors. The slope of 





 http://ahajournals.org by on July 9, 2021
